RxDoctor Payments Data

Christian Gocke

Internal Medicine · Baltimore, MDNPI 1962645143

Payments from drug & device makers

What this record shows

This record is dominated by education: $43 of the $43 with a category attached, or 100.0%. Every reported general payment came from a single manufacturer, AstraZeneca. That places this record below the midpoint for internal medicine clinicians in MD, where the typical reported total is $161.

$43in general payments, 2019–2025

Across 1 payment — averaging $43.25 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$43
$725,063in research payments, 2019–2025

Across 35 payments — averaging $20,716 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Takeda Pharmaceuticals U.S.A., Inc.$390K
  • Regeneron$253K
  • National Marrow Donor Program$56K
  • Janssen Research & Development, LLC$26K

What the payments were for

  • Education$43100%

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AstraZeneca1$43

How this compares

$43 in reported general payments places this provider in the 30th percentile of 2,979 internal medicine providers in Maryland.

See all internal medicine providers in Maryland

Medicare billing

Part B allowed, 2024
$66,253
Medicare patients
139
Services billed
696

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RevlimidLenalidomide140$2,378,660
PomalystPomalidomide44$957,153
EliquisApixaban15$12,089
Acyclovir50$1,348
Dexamethasone58$1,038

Paid to pharmacies, not to this prescriber.

Other internal medicine in Baltimore

See the full list for Maryland

Where these figures come from

Is this you, or does something look wrong? →